A panoramic view of inflammation: Etiology, pathophysiology, and management strategies

Lokesh Paranjape, Divya Ashok Kulkarni*

Department of Pharmacy Practice,
Shree Chanakya Education Society's Indira College of Pharmacy, Pune-411033
Email: kulkarni.divya13@gmail.com

Abstract

Inflammation, a fundamental biological process, plays a pivotal role in host defense and disease pathogenesis. This paper explores the triggers, mechanisms, impact, and management of inflammation. It highlights infectious agents, chemical/physical factors, and autoimmunity as key initiators, activating cellular components such as macrophages and neutrophils via pathways such as NF-kB and inflammasomes. While acute inflammation promotes healing, its dysregulation leads to chronic diseases like rheumatoid arthritis, cardiovascular disorders, and fibrosis. Traditional treatment involves NSAIDs, corticosteroids, and DMARDs, while emerging therapies focus on precise targeting of immune pathways and metabolic immunomodulation. Lifestyle modifications, including anti-inflammatory diets, also play a critical role. Unresolved issues persist regarding the transition from acute to chronic inflammation, necessitating further research into novel therapy targets and a personalized approach for effective resolutions.

Keywords: Inflammasomes, cytokines, autoimmune diseases, anti-inflammatory therapy

1. Introduction

Inflammation is the body's natural response to harmful stimuli like pathogens, damaged cells, or irritants, serving as a first line of defense and playing a key role in eliminating threats and initiating tissue repair. While acute inflammation is essential for healing, chronic inflammation can contribute to serious health issues such as cancer, cardiovascular disease, and autoimmune disorders (1,2). It triggers increased blood flow, immune activity, and chemical release, causing redness, heat, swelling, pain, and loss of function (3).

Pattern-recognition receptors (PRRs) are key in identifying specific molecular structures. These structures can be Pathogen-Associated Molecular Patterns (PAMPs) found on microorganisms or Damage-Associated Molecular Patterns (DAMPs) released by damaged or dying cells. Once PRRs detect these patterns, they activate inflammatory signaling pathways which kick-starts the body's inflammatory response (4).

2. Understanding inflammation

Inflammation is a biological response of vascular tissues to harmful stimuli like pathogens, damaged cells, or irritants. Its main goal is to eliminate the cause of injury, clear necrotic cells, and initiate tissue repair. Cardinal signs are redness, heat, swelling, pain, and loss of function resulting from increased blood flow, permeability, and chemical mediators aiding the immune response and repair. It involves the innate and

adaptive immune system with immune and non-immune cells, chemical mediators, and signaling pathways (5). Inflammation is classified as acute and chronic.

2.1. Acute inflammation

The body's innate response to injury and infection involves neutrophils and plasma proteins. It is short-lived, lasting minutes to days, and aimed at eliminating pathogens and promoting healing.

2.2. Chronic inflammation

It persists for weeks to years, often due to unresolved acute inflammation or ongoing exposure to irritants. It involves macrophages, lymphocytes, and plasma cells, leading to tissue damage and repair. Chronic inflammation can contribute to diseases like cardiovascular disease, diabetes, cancer, and autoimmune disorders. Thus, while inflammation is essential for host defense and tissue repair, its dysregulation can lead to significant pathology (6). Inflammation activates immune cells and releases cytokines like IL-1β, IL-6, and TNF-α, leading to vascular changes and immune cell migration to restore health (7).

3. Triggers of inflammation

3.1. Infectious agents

Infectious agents like bacteria, fungi, and parasites are major triggers of inflammation. Bacterial components like TLRs on immune cells lead to the release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and the recruitment of neutrophils to the infection site. Viral infections activate innate immune response through recognition of viral nucleic acids by TLRs and RIG-I-like receptors, including interferon production and inflammation. Fungal pathogens like Candida albicans stimulate inflammasomes activation, while parasitic infection provokes chronic inflammatory responses through antigen presentation and cytokine secretion, contributing to pathogen clearance but may cause tissue damage (8).

3.2. Physical chemical triggers

Physical injury, such as trauma, burns, or radiation, damages cells and tissues, releasing Damage-Associated Molecular Patterns (DAMPs) that activate innate immune receptors and trigger inflammation (9). Chemical irritants like pollutants (e.g., particulate matter, ozone), cigarette smoke, and toxins induce oxidative stress, which activates inflammatory pathways like NLRP3 inflammasome (10). Exposure to asbestos fibers causes persistent inflammation by stimulating macrophages and releasing cytokines, contributing to fibrosis and carcinogenesis. Alcohol abuse also promotes inflammation by disrupting gur barrier integrity and increasing systemic endotoxin levels, which further activate an immune response. These physical and chemical triggers initiate inflammation that can be protective but may cause chronic tissue damage if unresolved (11).

3.3. Autoimmune causes

Autoimmune diseases arise when the immune system mistakenly targets self-antigens, leading to chronic inflammation and tissue damage (12). In conditions like rheumatoid arthritis and systemic lupus erythematosus (SLE), autoantibodies and immune complexes activate complement and recruit inflammatory cells, sustaining inflammation (13). Genetic predispositions, such as specific HLA alleles, and environmental factors contribute to the loss of self-tolerance. Molecular mimicry, where microbial antigen resembles self-Persistent Autoimmune inflammation disrupts normal tissue function and underlies many chronic diseases, highlighting the need for targeted immunomodulatory therapies (14).

4. Molecular and cellular mechanisms

4.1. Cellular mechanism

Inflammation involves immune and non-immune cells eliminating pathogens and repairing tissues, Macrophages regulate phagocytosis, cytokines production (TNF-α, IL-1β, IL-6), remodeling, and polarizing into M1 or M2 phenotypes. Neutrophils respond rapidly with granules, reactive oxygen species ROS and neutrophil extracellular traps NETs. Dendritic cells release histamine and leukotrienes to increase permeability.

Lymphocytes (Th1, Th17, B cells) drive chronic inflammation via IFN-γ, IL-17, and autoantibodies. Endothelial cells help leukocyte adhesion and migration by expressing ICAM-1 and VCAM-1 (15).

4.2. Molecular mechanism

Inflammation is driven by conserved signaling pathways activated by pattern recognition receptors (PRRs), pathogen-associated molecular patterns (PAMPs), and damage-associated molecular patterns (DAMPs) from microbes or stressed cells. PAMPs include microbial nucleic acids (unmethylated CpG motifs, double and single-stranded RNA) and components like peptidoglycans, lipoteichoic acid, and lipopolysaccharides (LPS). DAMPs include mitochondrial DNA, uric acid, S100 proteins, heat shock proteins, fibronectin, β-amyloid, advanced glycation end proteins (AGEs), and histone (16). These signals activate pathways like NF-kB, inducing transcription of pro-inflammatory cytokines (TNF-α, IL-1β) and chemokines (CXCL8) (17). The JAK-STAT pathway is triggered by IL-6 and IFN-γ, promotes leukocyte activation and chronic inflammation. Inflammasomes like NLRP3 activate caspase-1, maturing IL-1β and IL-18. Cytokines enhanced endothelial adhesion, molecule expression and acute phase response; chemokines attract neutrophils and monocyte/macrophages; lipid mediators (PGE2, LTB4) regulate vasodilation, pain, and cell movement. Reactive oxygen species ROS eliminate pathogens but contribute to oxidative tissue damage during chronic inflammation (18).

4.3. Regulation and resolution mechanism

To limit damage, inflammation is controlled by molecules “brakes”. Proteins like Tollip, SIRT1, and IRAK-M inhibit NF-κB activation, reducing cytokine production. Autophagy and lysosomal fusion clear debris, adding resolution. Transcription factors CREB and TFEB induce anti-inflammatory and tissue repair genes. Failure of these pathways can cause chronic inflammation, contributing to autoimmune disease, atherosclerosis, and metabolic syndrome (19).



Figure 1. Mechanism of inflammation

5. Impact on inflammation

5.1. Physiological role (defense and healing)

Inflammation is crucial for host defense and tissue repair. Acute inflammation eliminates pathogens through immune cell recruitment and cytokine-mediated pathogen clearance (20). In tendon-bone healing, controlled inflammation clears debris and stimulates collagen synthesis. While immune cells like fibroblasts promote regeneration. Early-stage bone repair also relies on inflammatory signals to initiate callus formation. Similarly, skin wound healing involves immune cells releasing growth factors that coordinate tissue regeneration. These processes underscore inflammation’s protective role in restoring homeostasis (21).

5.2. Pathological consequences (chronic diseases, tissue damage)

Uncontrolled inflammation drives chronic diseases and tissue destruction. Long-term inflammatory signaling disrupts extracellular matrix (ECM) balance, leading to fibrosis and organ dysfunction. In bone, prolonged inflammation exacerbates osteoclast activities, increasing fracture risk and osteoporosis (22). Chronic

inflammation in wounds delays healing, causing pathological scarring or a non-healing ulcer. Overactive immune responses in autoimmune disorders like rheumatoid arthritis perpetuate joint damage, while oxidative stress from inflammatory mediators worsens tissue injury (23).

5.3. Disease association

5.3.1. **Autoimmune disorders:** Rheumatoid arthritis is characterized by systemic inflammation, where cytokine imbalances (e.g., TNF-α, IL-6) accelerate joint erosion and increase cardiovascular mortality.

5.3.2. **Cardiovascular diseases:** Chronic inflammation in Rheumatoid arthritis promotes endothelial dysfunction, elevating cardiovascular mortality risk (24).

5.3.3. **Fibrosis:** TGF-β-driven inflammation in organs like the lings and liver results in ECM accumulation and functional decline (25).

6. Management and therapeutic approach

6.1. Conventional treatment

Conventional management of inflammation primarily involves pharmacological interventions aimed at controlling symptoms and preventing disease progression. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen are commonly used to reduce pain and swelling. Corticosteroids like prednisone provide potent anti-inflammatory effects, especially in acute exacerbation. Disease-modifying antirheumatic drugs (DMARDs), including methotrexate and sulfasalazine, are used in chronic conditions such as RA to slow down disease progression. Biologic agents targeting specific immune pathways, such as TNF inhibitors (e.g., adalimumab, infliximab) and interleukin blockers, have revolutionized treatment by providing targeted suppression of inflammation. These conventional therapies aim to control the inflammatory process, preserve tissue function, and improve quality of life. However, long-term use of some agents, especially NSAIDs and corticosteroids, carries risks such as gastrointestinal, cardiovascular, and immunosuppressive effects (26).

6.2. Emerging therapy

Recent advancement in inflammation management emphasizes precision targeting in immune pathways. Dual inflammasome inhibitors like ADS032, which block NLRP1 and NLRP3, offer broad therapeutic potential for skin and systemic disorders. NLRP3-specific inhibitors (Inzomelid, MCC950) show efficacy in neurodegenerative models by curbing chronic inflammation. Stem cell therapies, including mesenchymal cell and their exosomes, modulate neuroinflammation without exacerbating pathology, while hematopoietic stem cell transplantation achieves remission in refractory cases. Metabolic immunomodulation reprograms the T-cell pathway to reduce inflammation in colitis and multiple sclerosis models, minimizing systemic immunosuppression risk. Complement inhibitors (SAR445088, C5a blockers) and cytokine modulators (GM-CSF inhibitors) target upstream drivers of tissue damage and cognitive decline in Alzheimer's trials. Bruton Tyrosine Kinase and Janus kinase inhibitors refine B-cell and cytokine signaling in arthritis and bowel diseases. These approaches- spanning biologics, small molecules, and cellular therapies- prioritize specificity to enhance efficacy and safety, making a shift toward personalized anti-inflammatory medicine (27).

6.3. Lifestyle and prevention

Anti-inflammatory diets, particularly those rich in fruits, vegetables, whole grains, nuts, legumes, and omega-3 fatty acids, have demonstrated effectiveness in managing chronic inflammation and improving quality of life for patients with conditions such as rheumatoid arthritis and chronic pain. Clinical studies, including a 2023 pilot trial, show that adherence to an anti-inflammatory dietary pattern correlates with reduced pain, stress, depression, and better

sleep, likely due to decreased intake of pro-inflammatory foods and increased consumption of anti-inflammatory nutrients. These diets act by lowering pro-inflammatory mediators and oxidative stress, thereby reducing systemic inflammation. While not a cure, an inflammatory diet serves as a valuable adjunct to medical therapy. Integrating complementary lifestyle modifications regular physical activity, stress management, adequate sleep, smoking cessation, and weight control, further enhances anti-inflammatory effects and overall health outcomes. Together, these strategies help to manage inflammation and may reduce reliance solely on pharmacological treatment.

Figure 2. Inflammation management: Treatments and lifestyle

7. Challenges and future directions

7.1. Unresolved issues in inflammation research

Key unresolved questions include the precise mechanism driving the transition from acute to chronic inflammation in diseases like long COVID and autoimmune disorders. Current therapies often fail to resolve inflammation completely, as many pathways (e.g., NLRP3 inflammasome activity, cytokine storms) remain difficult to target without immunosuppressive side effects. Additionally, the interplay between inflammation, aging, and metabolic dysregulation is poorly understood, limiting tailored therapeutic strategies.

7.2. Potential areas for new therapies and research focus

Emerging approaches focus on modulating immune cell migration (e.g., targeting miR-199 to suppress neutrophil trafficking without immunosuppression) and restoring anti-inflammatory homeostasis (e.g., boosting endogenous anti-inflammatory lipids or mediators like resolvins). Innovation in precision medicine, such as single-cell profiling of immune-neuronal interaction, could uncover novel targets like thrombospondin-1 (TSP1) to resolve inflammatory pain. Additionally, the “amalgamation” hypothesis proposes rebalancing pro- % anti-inflammatory mediators rather than broadly suppressing inflammation, opening avenues for therapies targeting specific molecular checkpoints (28).

8. Conclusion

Inflammation is a double-edged sword, essential for defense and healing but harmful when dysregulated, driving chronic diseases like cancer and autoimmune disorders. Advances in understanding its molecular mechanisms (e.g., NLRP3, NF-κB) enable targeted therapies, though unresolved challenges in resolving chronic inflammation necessitate innovative strategies to restore immune balance.

References

1. Oronsky B, Caroen S, Reid T. What exactly is inflammation (and what is it not?) Int J Mol Sci. 2022 Nov 28;23(23):14905.
2. Chavda VP, Feehan J, Apostolopoulos V. Inflammation: the cause of all diseases. Cells. 2024 Nov 18;13(22):1906.
3. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol. 2007 Feb;147(2):227–35.
4. Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1(1):1–13.
5. Megha KB, Joseph X, Akhil V, Mohanan PV. Cascade of immune mechanism and consequences of inflammatory disorders. Phytomedicine. 2021 Oct 1;91:153712.
6. Ephraim R, Fraser S, Devereaux J, Stavely R, Feehan J, Eri R, et al. Differential gene expression of checkpoint markers and cancer markers in mouse models of spontaneous chronic colitis. Cancers (Basel). 2023 Sep 29;15(19):4793.
7. Lionakis MS, Netea MG. Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog. 2013 Jan;9(1):e1003079.
8. Lim EY, Kim GD. Particulate matter-induced emerging health effects associated with oxidative stress and inflammation. Antioxidants (Basel). 2024 Oct 1;13(10):2050.
9. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1666–80.
10. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228–33.
11. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001 Oct 15;108(8):1097–104.
12. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017 Dec 14;9(6):7204–18.
13. Thermo Fisher Scientific. Inflammation overview [Internet]. [cited 2025 Apr 24]. Available from: https://www.thermofisher.com/in/en/home/life-science/cell-analysis/cell-analysis-learning-center/immunology-at-work/inflammation-overview.html
14. Kuprash DV, Nedospasov SA. Molecular and cellular mechanisms of inflammation. Biochemistry (Mosc). 2016 Nov 1;81(11):1237–9.
15. Crockett-Torabi E, Ward PA. The role of leukocytes in tissue injury. Eur J Anaesthesiol. 1996 May;13(3):235–46.
16. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018 Jan 1;281(1):8–27.
17. Rahtes A, Geng S, Lee C, Li L. Cellular and molecular mechanisms involved in the resolution of innate leukocyte inflammation. J Leukoc Biol. 2018 Sep 1;104(3):535–48.
18. Cioce A, Cavani A, Cattani C, Scopelliti F. Role of the skin immune system in wound healing. Cells. 2024 Apr 1;13(7):942.
19. Torres HM, Arnold KM, Oviedo M, Westendorf JJ, Weaver SR. Inflammatory processes affecting bone health and repair. Curr Osteoporos Rep. 2023 Dec 1;21(6):842–53.
20. Antar SA, Ashour NA, Marawan ME, Al-Karmalawy AA. Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation. Int J Mol Sci. 2023 Feb 1;24(4):3532.
21. Ma Z, Wu S, Guo Y, Ouyang S, Wang N. Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in US patients with rheumatoid arthritis. Front Nutr. 2024;11:1267651.
22. Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy: current therapeutic approaches and future outlooks. Immunotargets Ther. 2024;13:99–110.
23. Andonian BJ, Hippensteel JA, Abuabara K, Boyle EM, Colbert JF, Devinney MJ, et al. Inflammation and aging-related disease: a transdisciplinary inflammaging framework. Geroscience. 2024 Feb 1;47(1):515–33.
24. Diet Review: Anti-Inflammatory Diet - The Nutrition Source [Internet]. [cited 2025 Apr 25]. Available from: https://nutritionsource.hsph.harvard.edu/healthy-weight/diet-reviews/anti-inflammatory-diet/
25. Nutrients | Special Issue: Anti-Inflammatory Diet and Chronic Inflammation [Internet]. [cited 2025 Apr 25]. Available from: https://www.mdpi.com/journal/nutrients/special_issues/SK6I8IB484
26. Foods you should eat to help fight inflammation - Harvard Health [Internet]. [cited 2025 Apr 25]. Available from: https://www.health.harvard.edu/nutrition/foods-you-should-eat-to-help-fight-inflammation
27. Nathan C. Nonresolving inflammation redux. Immunity. 2022 Apr 12;55(4):592–605.
28. Research suggests new approach for treating inflammation [Internet]. [cited 2025 Apr 26]. Available from: https://www.purdue.edu/research/features/stories/research-suggests-new-approach-for-treating-inflammation/